Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies [Accessibility Statement] Skip NavigationSpinoff from Novartis AG's acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platformLead candidates ATR 1072 and ATR 1086 expected to enter clinical trials for PRKAG2 syndrome and PLN cardiomyopathy, respectivelySAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ...

Adds Avidity’s differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipelinePotentially unlocks multi-billion-dollar opportunities with planned product launches before 2030Strengthens late-stage pipeline to further support 2025-2030 net sales CAGR of 5-6% cc and mid to long term growth outlook Basel, February 27, 2026 -- Novartis AG (NYSE: NVS) today announced that it has successfully completed its acquisition of Av ...

Core Viewpoint - TransCode Therapeutics has published a manuscript detailing a novel tumor-selective immunotherapy approach that activates innate immune signaling specifically within cancer cells, enhancing drug delivery imaging capabilities [1]. Group 1: Research and Development - The published study in the journal Molecular Imaging and Biology describes a template-driven RIG-I agonist strategy that selectively activates RIG-I signaling in tumor cells by utilizing overexpressed oncogenic microRNAs, such as miRNA-21, as assembly templates [1]. - This new approach aims to address challenges associated with RIG-I agonists, including off-target immune activation and inefficient systemic delivery [1]. - The findings suggest a method to engage innate immune pathways directly within tumor cells while minimizing systemic toxicity, potentially advancing RIG-I-based immunotherapy towards clinical relevance [1]. Group 2: Clinical Trials and Therapeutic Candidates - TransCode's TTX delivery platform, which is currently under evaluation in clinical trials, is expected to enhance the translational feasibility of this immunotherapy approach [1]. - The company's lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis [1]. - TransCode's portfolio includes other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells [1].

Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders [Accessibility Statement] Skip NavigationSAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (NASDAQ: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates ("AOCsâ"¢") to profoundly improve people's lives, today announced that it intends to convene its upcoming special meeting of stockholders (the "Special M ...

Core Insights - TransCode Therapeutics has submitted an Investigational New Drug (IND) application amendment to the FDA for a Phase 2a clinical trial of its lead candidate TTX-MC138, in collaboration with Quantum Leap Healthcare Collaborative [1][3] Group 1: Clinical Trial Details - The Phase 2a trial will enroll up to 45 patients with colorectal cancer who have completed standard therapy and have positive circulating tumor DNA (ctDNA) markers [2] - The trial aims to evaluate the biological and clinical activity of TTX-MC138 in the minimal residual disease (MRD) setting, which is believed to offer significant opportunities for improving long-term outcomes [2] - The trial is set to begin in the first half of 2026 and will be led by Dr. Paula Pohlmann from MD Anderson Cancer Center [2] Group 2: Collaboration and Program Expansion - The IND submission is a significant step in TransCode's clinical development program, enhancing the potential benefits of TTX-MC138 for patients [3] - The collaboration with Quantum Leap's PRE-I-SPY program marks the first expansion of this platform into colorectal cancer [3][4] - The clinical trial will be conducted at various sites within the PRE-I-SPY Platform Network, which includes members of the National Cancer Center Network [4] Group 3: Company Overview - TransCode Therapeutics is focused on immuno-oncology and RNA therapeutics for high-risk and advanced cancers, with TTX-MC138 targeting metastatic tumors that overexpress microRNA-10b [5] - The company has a portfolio of first-in-class therapeutic candidates aimed at mobilizing the immune system to combat cancer cells [5]

Core Insights - TransCode Therapeutics, Inc. announced preclinical research supporting its lead candidate TTX-MC138 for glioblastoma multiforme (GBM) treatment, published in the Journal of Functional Biomaterials [1][2] Group 1: Research Findings - Glioblastoma is identified as the most aggressive primary brain cancer, with a median survival of under two years despite current treatments [2] - The study demonstrated that TTX-MC138 can be delivered to human GBM tumors in murine models via intravenous injection, leading to sustained target engagement and a five-fold increase in apoptotic activity in tumors [3][9] - Treatment with TTX-MC138 resulted in a statistically significant increase in survival rates in the studied models [3][9] Group 2: Development and Future Plans - The findings support the capability of TransCode's TTX platform to deliver antisense oligonucleotides (ASOs) to brain tumors, overcoming delivery barriers such as nucleic acid degradation [4] - TTX-MC138 has completed IND enabling studies, pharmacokinetics, biodistribution, and toxicity studies, showing safety in Phase I clinical trials for non-CNS cancers, paving the way for future clinical evaluations in GBM patients [4][6] - A Phase 2a clinical trial for TTX-MC138 is anticipated to begin in the first half of 2026, highlighting the translational relevance of this therapeutic approach [6] Group 3: Company Overview - TransCode Therapeutics is focused on immuno-oncology and RNA therapeutics for high-risk and advanced cancers, with TTX-MC138 targeting metastatic tumors that overexpress microRNA-10b [7] - The company has a portfolio of first-in-class therapeutic candidates aimed at mobilizing the immune system to combat cancer cells [7]

Core Viewpoint - Wave Life Sciences Ltd. has announced the pricing of its public offering of ordinary shares and pre-funded warrants, aiming to raise approximately $350 million before expenses [1][2]. Group 1: Offering Details - The public offering consists of 15,789,475 ordinary shares priced at $19.00 each, along with pre-funded warrants for 2,631,578 ordinary shares at an offering price of $18.9999 [1][2]. - The offering is expected to close on or about December 11, 2025, subject to customary closing conditions [2]. Group 2: Underwriters - Jefferies, Leerink Partners, and BofA Securities are acting as joint book-running managers for the offering, while Truist Securities and Mizuho are serving as book-runners [3]. Group 3: Company Overview - Wave Life Sciences is a biotechnology company focused on RNA medicines, utilizing its PRISM® platform to address both rare and common disorders [6]. - The company's pipeline includes clinical programs targeting obesity, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington's disease, along with several preclinical programs [6].

Core Insights - Novartis (NVS) projects a compounded annual growth rate (CAGR) of 5-6% for sales from 2025 to 2030, with an upgraded sales guidance for 2024-2029 to 6% from 5% due to strong growth drivers and upcoming launches [1][7] - The company faces generic competition for its drug Entresto, but strong performances from products like Kisqali, Kesimpta, Pluvicto, and Scemblix support its momentum [2][12] - Novartis raised its peak sales guidance for Kisqali to over $10 billion from over $8 billion, reflecting its strong performance [3] Sales Performance - Kisqali's sales increased by 68% to $1.33 billion in Q3, driven by growth in the U.S. market, particularly from the early breast cancer indication [4] - Scemblix sales surged by 95% to $358 million in Q3, supported by growth in chronic myeloid leukemia and new indications in the U.S. and Japan [5] - Novartis has eight de-risked, in-market drugs with peak sales potential ranging from $3 billion to $10 billion [5] Regulatory Approvals and Pipeline - Novartis received FDA approval for remibrutinib (Rhapsido) as an oral treatment for chronic spontaneous urticaria, marking it as the first FDA-approved Bruton's tyrosine kinase inhibitor for this condition [8] - The company is focused on four core therapeutic areas: cardiovascular-renal-metabolic, immunology, neuroscience, and oncology [8] - Key pipeline candidates include ianalumab, pelacarsen, OAV101 IT, del-desiran, abelacimab, and farabursen [9] Strategic Acquisitions - Novartis announced the acquisition of Avidity Biosciences for $12 billion to enhance its neuroscience pipeline, with the deal expected to close in the first half of 2026 [10][11] - The acquisition of Tourmaline Bio for $1.4 billion adds a phase III-ready candidate to Novartis' cardiovascular pipeline [13] - Novartis has entered into collaboration agreements with Monte Rosa Therapeutics and Arrowhead Pharmaceuticals to expand its research capabilities [14][15]

Core Insights - Avidity Biosciences has launched a Managed Access Program (MAP) for its investigational therapy delpacibart zotadirsen (del-zota) aimed at individuals with Duchenne muscular dystrophy mutations amenable to exon 44 skipping (DMD44) in the U.S. [1][2] - The MAP is designed to provide del-zota to eligible patients quickly, with enrollment expected to begin by the end of 2025 [2][3] - Avidity plans to submit a Biologics License Application (BLA) for del-zota in 2026 following a pre-BLA meeting with the FDA [3] Company Overview - Avidity Biosciences focuses on developing a new class of RNA therapeutics known as Antibody Oligonucleotide Conjugates (AOCs) [6] - The company aims to address previously unreachable targets and diseases using its proprietary AOC platform [6] - Avidity is advancing clinical programs for rare muscle diseases, including Duchenne muscular dystrophy, and has received multiple designations from the FDA for del-zota [5][6] Product Details - Del-zota is designed to skip exon 44 of the dystrophin gene, enabling dystrophin production in patients with DMD44 [5] - The Phase 1/2 EXPLORE44 trial demonstrated significant increases in dystrophin production and improvements in muscle function, with a favorable safety profile [5] - Del-zota has received designations such as Rare Pediatric Disease, Orphan Drug, Fast Track, and Breakthrough Therapy from the FDA [5]

Core Insights - Avidity Biosciences has entered into a definitive merger agreement with Novartis for a total equity value of approximately $12 billion, which is expected to maximize value for investors and enhance the global reach of Avidity's neuroscience pipeline [1][2][6] - Avidity's del-zota program has shown promising one-year data, demonstrating sustained muscle protection and significant improvement in disease progression for patients with Duchenne muscular dystrophy [1][6] - The company reported a strong balance sheet with approximately $1.9 billion in cash, cash equivalents, and marketable securities as of September 30, 2025, which is expected to fund operations until mid-2028 [1][6] Company Announcements - The merger with Novartis is set to close in the first half of 2026, following the separation of Avidity's early-stage precision cardiology programs into a new public company, SpinCo [1][6] - Avidity's CEO, Sarah Boyce, will transition to chair of the board of SpinCo, while Kathleen Gallagher will lead SpinCo as CEO [6] Financial Results - For the third quarter of 2025, Avidity reported collaboration revenues of $12.5 million, a significant increase from $2.3 million in the same period of 2024 [13] - Research and development expenses for Q3 2025 were $154.9 million, compared to $77.2 million in Q3 2024, reflecting increased costs associated with advancing key programs [13] - The net loss for Q3 2025 was $174.4 million, compared to a net loss of $80.4 million in Q3 2024 [13] Clinical Development Progress - Avidity's del-zota program has received Breakthrough Therapy designation from the FDA and is on track for a BLA submission in 2026 [6] - The company is advancing its del-desiran program for myotonic dystrophy type 1, with topline data from the Phase 3 HARBOR trial expected in the second half of 2026 [6] - Avidity is also progressing its del-brax program for facioscapulohumeral muscular dystrophy, with data readouts expected in 2026 [6]